Skip to main content
. 2025 Feb 11;9(2):102702. doi: 10.1016/j.rpth.2025.102702

Figure 2.

Figure 2

Flowchart of study enrollment, grouping, and therapeutic management. HD-DXM, high-dose dexamethasone; ITP, immune thrombocytopenia; RTX, rituximab; P/CITP, persistent/chronic immune thrombocytopenia; TPO-RA, thrombopoietin receptor agonist.